Invex Therapeautics: Lands approval for phase three clinical trial in Germany

Invex Therapeutics (IXC) gains approval to start its IIH EVOLVE phase III clinical trial in Germany to treat patients with idiopathic intracranial hypertension (IIH) using Presendin
The approval was received from Germany’s Federal Institute for Drugs and Medical Devices and marks another step towards the commercialisation of Presendin
The trial will test 240 patients with newly-diagnosed IIH to assess the efficacy and safety of Presending versus a placebo
Invex entered an exclusive collaboration, manufacturing and supply agreement back in September 2021 with Peptron for Presendin in IIH for all major markets except for South Korea
IXC shares are up 2.22 per cent to 46 cents at 10:46 am AEDT

March 20, 2023